American Journal of Biomedical Research
ISSN (Print): 2328-3947 ISSN (Online): 2328-3955 Website: http://www.sciepub.com/journal/ajbr Editor-in-chief: Hari K. Koul
Open Access
Journal Browser
Go
American Journal of Biomedical Research. 2020, 8(2), 40-46
DOI: 10.12691/ajbr-8-2-3
Open AccessArticle

Puerarin Attenuates Transforming Growth Factor Beta-1 Induced Hypertrophic Responses and Smad Proetin Upregulation in Neonatal Rat Cardiomyocytes

Yongying Shi1, 2, Aijun Liu3, Junjiang Lu4, Guangyuan Chen1, Shiming Liu2, 5, Minsheng Chen6 and Chengfeng Luo2, 5,

1The First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, Guangdong, China

2Guangzhou Institute of Cardiovascular Disease, Guangzhou 510080, Guangdong, China

3Cardiovascular surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

4Neurology, Guangzhou chest hospital, Guangzhou 510095, Guangdong, China

5Cardiovascular medicine, The Second Affiliated Hospital of Guangzhou Medical College, Guangzhou 510260, Guangdong, China

6Cardiovascular medicine, Southern Medical University, Guangzhou 510515, Guangdong, China

Pub. Date: June 27, 2020

Cite this paper:
Yongying Shi, Aijun Liu, Junjiang Lu, Guangyuan Chen, Shiming Liu, Minsheng Chen and Chengfeng Luo. Puerarin Attenuates Transforming Growth Factor Beta-1 Induced Hypertrophic Responses and Smad Proetin Upregulation in Neonatal Rat Cardiomyocytes. American Journal of Biomedical Research. 2020; 8(2):40-46. doi: 10.12691/ajbr-8-2-3

Abstract

Recent studies have suggested that puerarin may attenuate cardiac hypertrophy in mice; however, the underlying mechanism remains unclear. To investigate the role of puerarin in transforming growth factor beta 1 (TGF-β1)-induced cardiac hypertrophy and the underlying mechanisms. Primary neonatal rat cardiomyocytes (NRCMs) were isolated form the heart of neonatal Wistar rats (1- to 2-day-old) and treated with different doses of puerarin (0,0.1,1or 5 g/L) in the presence of TGF-β1 (3 μg/L) to investigate the effect of puerarin on TGF-β1-induced hypertrophic changes and Smad protein alterations. RNA and protein biosynthesis in NRCMs were evaluated by synpropidium iodide staining and [3H]-leucine incorporation, respectively. Gene expression alterations were determined using quantitative real-time PCR and Western blot analysis. Compared with Smad2 knockdown, puerarin treatment (1 g/L) exhibited similar but stronger effects in abrogating TGF-β1-induced RNA and protein biosynthesis as well as fetal gene upregulation in NRCMs. In addition, puerarin treatment (1 g/L) could remarkably reverse TGF-β1-induced upregulation of Smad protein expression in NRCMs, suggesting that deactivation of the Smad signaling is possibly involved in the antihypertrophic role of puerarin. Our data suggest that puerarin may protect cardiomyoctyes against TGF-β1-induced hypertrophic responses and Smad signaling activation, providing basic dosage information and possible targets for puerarin treatment in animal models.

Keywords:
cardiomyocyte hypertrophy transforming growth factor-β1 the Smad signaling

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 5

References:

[1]  Opie L, Commerford P, Gersh BJ and Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367: 356-367
 
[2]  Tham YK, Bernardo BC, Ooi JY, Weeks KL and McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 2015; 89: 1401-1438.
 
[3]  Shimizu I and Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016; 97: 245-262.
 
[4]  Hou J and Kang YJ. Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther. 2012; 135: 337-354.
 
[5]  Frey N, Richardson JA and Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci U S A 2000; 97: 14632-14637.
 
[6]  Samak M, Fatullayev J, Sabashnikov A, Zeriouh M, Schmack B, Farag M, Popov AF, Dohmen PM, Choi YH, Wahlers T and Weymann A. Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis. Med Sci Monit Basic Res 2016; 22: 75-79.
 
[7]  Song XP, Chen PP and Chai XS. Effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats. ZhongguoYao Li Xue Bao 1988; 9: 55-58.
 
[8]  Zhang S, Chen S, Shen Y, Yang D, Liu X, Sun-Chi AC and Xu H. Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol Pharm Bull 2006; 29: 945-950.
 
[9]  Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC and Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod 2003; 66: 788-792.
 
[10]  Gao L, Ji X, Song J, Liu P, Yan F, Gong W, Dang S and Luo Y. Puerarin protects against ischemic brain injury in a rat model of transient focal ischemia. Neurol Res 2009; 31: 402-406.
 
[11]  Liu CM, Ma JQ and Sun YZ. Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. Food Chem Toxicol 2011; 49: 3119-3127.
 
[12]  Choo MK, Park EK, Yoon HK and Kim DH. Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol Pharm Bull 2002; 25: 1328-1332.
 
[13]  Huang F, Liu K, Du H, Kou J and Liu B. Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an IKKbeta/IRS-1-dependent manner. Biochimie 2012; 94: 1143-1150.
 
[14]  Zhang H, Zhang L, Zhang Q, Yang X, Yu J, Shun S, Wu Y, Zeng Q and Wang T. Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). Mol Cell Biochem 2011; 352: 117-123.
 
[15]  Yang L, Yao D, Yang H, Wei Y, Peng Y, Ding Y and Shu L. Puerarin Protects Pancreatic beta-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling. Mol Endocrinol 2016; 30: 361-371.
 
[16]  Malaivijitnond S, Tungmunnithum D, Gittarasanee S, Kawin K and Limjunyawong N. Puerarin exhibits weak estrogenic activity in female rats. Fitoterapia 2010; 81: 569-576.
 
[17]  Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF and Frangogiannis NG. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007; 116: 2127-2138.
 
[18]  Xia Y, Lee K, Li N, Corbett D, Mendoza L and Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 2009; 131: 471-481.
 
[19]  Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, Gan HW, Yang Z, Li H and Tang QZ. Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol 2014; 63: 73-81.
 
[20]  Chen G, Pan SQ, Shen C, Pan SF, Zhang XM and He QY. Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways. Acta Pharmacol Sin 2014; 35: 463-475.
 
[21]  Zhang X, Liu Y and Han Q. Puerarin Attenuates Cardiac Hypertrophy Partly Through Increasing Mir-15b/195 Expression and Suppressing Non-Canonical Transforming Growth Factor Beta (Tgfbeta) Signal Pathway. Med Sci Monit 2016; 22: 1516-1523.
 
[22]  Parker TG, Packer SE and Schneider MD. Peptide growth factors can provoke fetal contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85: 507-514.
 
[23]  Deten A, Holzl A, Leicht M, Barth W and Zimmer HG. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001; 33: 1191-1207.
 
[24]  Li JM and Brooks G. Differential protein expression and subcellular distribution of TGFbeta1, beta2 and beta3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997; 29: 2213-2224.
 
[25]  Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schluter KD and Bohm M. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002; 283: H1253-1262.
 
[26]  Simpson P, McGrath A and Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982; 51: 787-801.
 
[27]  Frankfurt OS. Flow cytometric analysis of double-stranded RNA content distributions. Methods Cell Biol 1990; 33: 299-304.
 
[28]  Luo JD, Xie F, Zhang WW, Ma XD, Guan JX and Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001; 132: 159-164.
 
[29]  Villar AV, Cobo M, Llano M, Montalvo C, Gonzalez-Vilchez F, Martin-Duran R, Hurle MA and Nistal JF. Plasma levels of transforming growth factor-beta1 reflect left ventricular remodeling in aortic stenosis. PLoS One 2009; 4: e8476.
 
[30]  Ayca B, Sahin I, Kucuk SH, Akin F, Kafadar D, Avsar M, Avci, II, Gungor B, Okuyan E and Dinckal MH. Increased Transforming Growth Factor-beta Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy. Clin Cardiol 2015; 38: 371-377.
 
[31]  Euler-Taimor G and Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 2006; 69: 15-25.
 
[32]  Khan R and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
 
[33]  Bjornstad JL, Skrbic B, Marstein HS, Hasic A, Sjaastad I, Louch WE, Florholmen G, Christensen G and Tonnessen T. Inhibition of SMAD2 phosphorylation preserves cardiac function during pressure overload. Cardiovasc Res 2012; 93: 100-110.
 
[34]  Zhang NB, Huang ZG, Cui WD and Ding BP. Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat. J Ethnopharmacol 2011; 138: 737-740.
 
[35]  Liu B, Wu Z, Li Y, Ou C, Huang Z, Zhang J, Liu P, Luo C and Chen M. Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. Biochem Biophys Res Commun 2015; 464: 908-915.